Related to EC Follows FDA and Approves Lilly’s Erectile Dysfunction Drug for BPH

• EC Clears HGS and GSK’s Systemic Lupus Erythematosus Antibody Therapy Benlysta
  
• Amgen’s Xgeva Approved by EC for Treating SREs in Adults with Solid Tumor-Related Bone Metastases
  
• EMA Recommends Cautious Prescribing of Takeda's Actos due to Bladder Cancer Risk
  
• EC Conditionally Approves Biogen Idec’s Multiple Sclerosis Drug Fampyra
  
• EC Approves Roche’s RoActemra for Treating Active Systemic Juvenile Idiopathic Arthritis
  
• EC Approves BI’s Pradaxa for Preventing Stroke in Atrial Fibrillation Patients
  
• EC Clears Roche’s Tarceva as Monotherapy Against Metastatic NSCLC with EGFR Mutations
  
• EC Clears Novartis’ Afinitor for Treating Advanced Pancreatic NET
  
• EC Clears Janssen-Cilag’s Zytig as Combination Therapy for Castration-Resistant Prostate Cancer
  
• EC Clears Pfizer’s Pneumococcal Vaccine for Use in Individuals Over Age 50
  
• EC Sanction of DuoCort’s Plenadren Triggers ViroPharma’s $33M Acquisition of Swedish Firm
  
• Pfizer’s Vyndaqel Gets EC Approval for Transthyretin Familial Amyloid Polyneuropathy Therapy
  
• EC Clears Novartis’ Blood Pressure Therapy
  
• EC Clears Gilead’s Single-Pill Triple-Drug HIV-1 Therapy
  
• Nearly Two-to-One Majority Sees FDA or EMA Approval of Gene Therapy by 2013
  
• Roche’s Cobas EGFR Mutation Test Granted CE Mark
  
• EC Clears Roche’s Avastin Against Ovarian Cancer
  
• Roche Gets CE Clearance for Two HCV Molecular Diagnostics
  
• EC Okays Merck Serono’s Rebif for Patients With Early Stages of MS
  
• EC Clears Roche, Plexxikon’s Zelboraf for BRAF V600-Mutated Melanoma